DEF: Ultralife Corporation Schedules 2025 Annual Meeting, Details Executive Compensation and Governance Updates

Ultralife Corporation has announced its 2025 Annual Meeting of Stockholders to be held on July 16, 2025, where shareholders will vote on director elections and auditor ratification, alongside disclosures on executive compensation and corporate governance.

Summary

• Ultralife Corporation will hold its 2025 Annual Meeting of Stockholders on Wednesday, July 16, 2025, at 9:00 A.M. Eastern Time in Atlanta, GA.
• Shareholders will vote on the election of five directors for a one-year term and the ratification of Freed Maxick P.C. as the independent registered public accounting firm for fiscal year 2025.
• The company is distributing proxy materials online to reduce environmental impact and costs, with paper copies available upon request.
• Non-employee director annual cash retainers increased for the July 1, 2024, to June 30, 2025, period, with the Board Chair receiving $108,000 and other non-employee directors receiving $73,500.
• Total compensation for non-employee directors in fiscal year 2024 was $411,578.
• For 2024, President and CEO Michael E. Manna's total compensation was $489,177, and CFO Philip A. Fain's was $445,987.
• Neither Mr. Manna nor Mr. Fain earned Short-Term Incentive Plan (STIP) awards for 2024, as the company did not meet its consolidated operating profit target of $12.0 million and consolidated revenue target of $169.5 million.
• In contrast, for 2023, Mr. Manna earned $278,214 and Mr. Fain earned $215,694 in STIP awards, which were paid in March 2024.
• Net income attributable to Ultralife was $6.312 million in 2024, a decrease from $7.197 million in 2023, but a significant improvement from a $(0.119) million loss in 2022.
• The company's total shareholder return (TSR) based on a $100 investment on December 31, 2021, was $123 by the end of 2024.
• Audit fees for Freed Maxick P.C. increased significantly from $565,700 in 2023 to $1,194,028 in 2024, partly due to the audit of internal controls over financial reporting and the acquisition of Electrochem Solutions, Inc.
• Bradford T. Whitmore, the Board Chair, beneficially owns 37.4% of the outstanding common stock, while all directors and executive officers as a group own 40.0%.

Sentiment

Score: 4

Explanation: The document is a standard proxy statement, but the failure to meet 2024 STIP targets for executive officers and the decrease in net income from 2023 to 2024 indicate a worse-than-expected financial performance for the most recent fiscal year, despite overall positive TSR and governance practices.

Positives

• The company maintains a strong corporate governance structure with independent directors, separate CEO and Board Chair roles, and active committees.
• All directors attended at least 75% of Board and committee meetings in 2024, indicating active engagement.
• The company has a clear Code of Ethics and Insider Trading Policy, prohibiting hedging and short sales by directors, officers, and employees.
• The company's net income attributable to Ultralife improved significantly from a loss of $(0.119) million in 2022 to a profit of $6.312 million in 2024.
• The company's total shareholder return (TSR) showed positive growth, with a $100 investment on December 31, 2021, growing to $123 by the end of 2024.
• Non-employee directors meet the stock ownership guidelines of at least $40,000 of common stock.

Negatives

• Named executive officers, Michael E. Manna and Philip A. Fain, did not earn Short-Term Incentive Plan (STIP) awards for 2024, indicating that the company did not meet its consolidated operating profit target of $12.0 million and consolidated revenue target of $169.5 million.
• Net income attributable to Ultralife decreased from $7.197 million in 2023 to $6.312 million in 2024.
• Audit fees increased substantially from $565,700 in 2023 to $1,194,028 in 2024, which could indicate increased complexity or scrutiny.

Risks

• Forward-looking statements involve risks and uncertainties and are based on management's beliefs and assumptions; actual results could differ materially.
• Risks and uncertainties are discussed in the company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings.
• The company assumes no obligation to update any forward-looking statements or information.

Future Outlook

The document contains forward-looking statements regarding environmental and social goals, commitments, and strategies, but cautions that actual results could differ materially due to various risks and uncertainties. The company assumes no obligation to update these statements.

Management Comments

• "We encourage you to vote your shares prior to the 2025 Annual Meeting of Stockholders."
• "By taking advantage of the Securities and Exchange Commission Rules permitting this internet distribution process, the Company will not only reduce the environmental impact of the 2025 Annual Meeting of Stockholders, but also reduce our costs of printing and distributing proxy materials."
• "Your continued interest in the Company is greatly appreciated. We look forward to a productive 2025 Annual Meeting of Stockholders."
• "We believe that the segregation of the roles of Board Chair from that of the President and Chief Executive Officer ensures better overall governance of our Company and provides meaningful checks and balances regarding our overall performance."
• "This structure allows our President and Chief Executive Officer to focus on our business while the Board Chair leads our Board of Directors in establishing corporate policy and enhancing our governance structure and practices. We believe this structure is appropriate for a company with our varied product portfolio addressing both commercial and defense markets."

Industry Context

Ultralife Corporation operates in the battery industry, serving both commercial and government/defense markets. The company's President and CEO, Michael E. Manna, has thirty years of experience in the battery industry and is recognized for expertise in rechargeable and primary battery cell design across multiple chemistries. The company's varied product portfolio addresses these diverse markets, and its corporate governance structure is deemed appropriate for this context.

Comparison to Industry Standards

• The company's executive compensation program is designed to deliver annual director compensation at the median levels for companies in similar industries and of similar size, based on periodic surveys of a peer group of micro-cap and public companies in the industry.
• The Short-Term Incentive Plan (STIP) target levels are set to achieve combined annual base salary and STIP awards at or near the 50th percentile for named executive officers at peer group companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification, impacting corporate leadership and financial oversight. Executive compensation and financial performance directly affect shareholder value and perception. Significant beneficial ownership by Board Chair (37.4%) and institutional investors (Visionary Wealth Advisors 6.6%, Dimensional Fund Advisors LP 6.2%) indicates concentrated ownership.
• Employees: Executive compensation structure, including base salaries and incentive plans, directly impacts named executive officers. The 401(k) plan with employer match benefits all active employees.
• Customers/Suppliers: Not directly addressed in this filing, but the company's focus on business strategy, growth, and operational performance (as incentivized by executive compensation) could indirectly impact relationships.
• Creditors: Financial performance metrics like net income and operating profit are relevant to creditors assessing the company's financial health.

Next Steps

• Stockholders are encouraged to vote their shares prior to the 2025 Annual Meeting.
• The 2025 Annual Meeting of Stockholders will be held on July 16, 2025, to elect directors and ratify the independent registered public accounting firm.
• The Audit and Finance Committee will consider the outcome of the auditor ratification vote when selecting the independent registered public accounting firm for 2025 and subsequent fiscal years.
• Stockholder proposals for the 2026 Annual Meeting must be submitted by January 28, 2026, for inclusion in the proxy statement.
• Stockholders intending to solicit proxies for director nominees must provide notice no later than 60 calendar days prior to the first anniversary of the 2025 Annual Meeting.

Key Dates

Recommendation

Keywords

Ultralife Corporation, SEC Filing, Proxy Statement, DEF 14A, Annual Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, Financial Performance, Stock Options, Shareholder Meeting, Risk Management, Battery Industry, Defense Markets, Commercial Markets